ArticleWorld journal of microbiology & biotechnology2025
Salicylic acid-induced upregulation of AtAACT and AtMVD expression enhances triterpene biosynthesis in Athelia termitophila.
Article in World journal of microbiology & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Triterpenoids exhibit great potential in the food and pharmaceutical industries and are the predominant secondary metabolites of Athelia termitophila (TMB). AtAACT catalyzes the conversion of acetyl-CoA and acetoacetate in mevalonate biosynthesis, while AtMVD catalyzes the decarboxylation of mevalonate diphosphate, producing key precursors essential for triterpenoid synthesis. To augment the biosynthesis of TMB triterpenes, we cloned the AtAACT and AtMVD genes into plasmids, which were subsequently used to transform Escherichia coli. The resulting bacterial strains were used for sequencing and bioinformatic analyses to elucidate the encoded amino acid sequences. Furthermore, salicylic acid (SA) was employed as an elicitor to enhance triterpene biosynthesis in TMB. The SA treatment was initiated on the 6th day of incubation and maintained continuously across all time points (36, 48, and 60 h and others), achieving a maximal triterpene concentration of 41.83 ± 0.5 mg/100 mL, corresponding to a 26% increase compared to the uninduced group. Comparative transcriptomic analysis showed that the expression of AtAACT and AtMVD was significantly upregulated in the SA-treated group compared to the control. This upregulation underscores the crucial roles of these genes in facilitating triterpene biosynthesis in TMB. Furthermore, qPCR temporal profiling revealed that AtAACT achieved peak transcript levels at 36 h post-induction, whereas AtMVD peaked at 48 h. This study provides an effective strategy to enhance TMB triterpene content and offers new insights into the mechanisms of SA-treated triterpene biosynthesis.
Indexed as
Identifiers
40011284What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.